Management of bone disease in multiple myeloma
Evangelos Terpos, James Berenson, Noopur Raje, G. David Roodman
Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.
Expert Review of Hematology
Bone Diseases
pamidronate
Diphosphonates
Clodronic Acid
Spontaneous Fractures
activin-A
RANKL
sclerostin
sotatercept
Wnt pathway
Terpos, E., Berenson, J., Raje, N., & Roodman, G. D. (2014). Management of bone disease in multiple myeloma. Expert Review of Hematology, 7(1), 113-125. https://doi.org/10.1586/17474086.2013.874943
Management of bone disease in multiple myeloma. / Terpos, Evangelos; Berenson, James; Raje, Noopur; Roodman, G. David.
In: Expert Review of Hematology, Vol. 7, No. 1, 02.2014, p. 113-125.
Terpos, E, Berenson, J, Raje, N & Roodman, GD 2014, 'Management of bone disease in multiple myeloma', Expert Review of Hematology, vol. 7, no. 1, pp. 113-125. https://doi.org/10.1586/17474086.2013.874943
Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple myeloma. Expert Review of Hematology. 2014 Feb;7(1):113-125. https://doi.org/10.1586/17474086.2013.874943
Terpos, Evangelos ; Berenson, James ; Raje, Noopur ; Roodman, G. David. / Management of bone disease in multiple myeloma. In: Expert Review of Hematology. 2014 ; Vol. 7, No. 1. pp. 113-125.
@article{08540083c0144ae298ccf1c795504b2e,
title = "Management of bone disease in multiple myeloma",
abstract = "Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.",
keywords = "activin-A, bisphosphonates, bone disease, denosumab, RANKL, sclerostin, sotatercept, Wnt pathway",
author = "Evangelos Terpos and James Berenson and Noopur Raje and Roodman, {G. David}",
journal = "Expert Review of Hematology",
publisher = "Expert Reviews Ltd.",
T1 - Management of bone disease in multiple myeloma
AU - Terpos, Evangelos
AU - Berenson, James
AU - Raje, Noopur
AU - Roodman, G. David
N2 - Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.
AB - Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.
KW - activin-A
KW - bisphosphonates
KW - bone disease
KW - denosumab
KW - RANKL
KW - sclerostin
KW - sotatercept
KW - Wnt pathway
JO - Expert Review of Hematology
JF - Expert Review of Hematology